Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New findings from Dr. Marcela Maus and team at Mass General Hospital reveal a surprising twist in CAR T-cell therapy:
While IFN-γ is often seen as a key player in immunotherapy, this study shows it may actually induce apoptosis in CD28-based CAR T cells, limiting their persistence and efficacy.
Knockout of IFN-γ receptor (IFN-γR) enhanced CAR T cell survival, memory, and anti-tumor activity – especially in solid tumors where CAR T success has been more elusive.
IFN-γR KO led to:
Better tumor control
Longer survival
Durable immune memory
Enhanced tumor cell apoptosis
This could mark a major advance in optimizing CAR T design for both liquid and solid cancers.”
Title: IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models
Journal: Science Translational Medicine
Authors: Stefanie R. Bailey, Hana N. Takei, Giulia Escobar, Michael C. Kann, Amanda A. Bouffard, Tamina Kienka, Valentina M. Supper, Alexander Armstrong, Diego Salas-Benito, Merle K. Phillips, Filippo Birocchi, Sonika Vatsa, Harrison Silva, Irene Scarfò, Marc Wehrli, Korneel Grauwet, Eli P. Darnell, Charlotte E. Graham, Mark B. Leick, Felix Korell, Trisha R. Berger, Marcela V. Maus
More posts featuring Yan Leyfman on OncoDaily.